CGEM — Cullinan Oncology Income Statement
0.000.00%
Last trade - 00:00
- $714.03m
- $247.15m
- 30
- 27
- 93
- 48
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 18.9 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 22.3 | 60.3 | 86.9 | -145 | 191 |
Operating Profit | -22.3 | -60.3 | -68 | 145 | -191 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -21.7 | -59.5 | -67.5 | 151 | -169 |
Provision for Income Taxes | |||||
Net Income After Taxes | -21.7 | -59.5 | -67.5 | 109 | -155 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -20.7 | -51.8 | -65.6 | 111 | -153 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -20.7 | -51.8 | -65.6 | 111 | -153 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.499 | -1.25 | -1.52 | -1.45 | -3.68 |
Dividends per Share |